Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Uber Technologies Inc (UBER) Price & Performance

Inovio Pharmaceuticals IncTrade
Uber Technologies IncTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Uber Technologies Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $76.09M), while Uber Technologies Inc trades at $78.3 (market cap $159.38B). The key difference: Uber Technologies Inc is far larger — about 2094.6× Inovio Pharmaceuticals Inc's market cap, and Uber Technologies Inc is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

INOUBER
Market Cap
$76.09M$159.38B
Sector
HealthIndustrials
52-Week High
$2.87$100.10
52-Week Low
$0.66$65.94
Enterprise Value
$47.10M$168.72B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.668, down 0.86% with bearish technical signals despite recent earnings beats. The company shows minimal revenue of $65,340 against substantial losses, with negative margins and cash flow challenges. Key catalyst is the FDA's October 2026 decision on INO-3107, while recent $20 million offering aims to fund operations.

High-risk biotech play with binary FDA outcome driving valuation. Analyst consensus is bullish (53% buy) with $3.25 price target, but fundamental weaknesses and litigation risks require caution. Success of INO-3107 is critical for turnaround, with current cash funding operations into early 2027.

Uber Technologies Inc

Uber (UBER) trades at $78.54, up 4.69% today, reflecting strong bullish momentum. The stock shows robust fundamentals with revenue growth from $44.0B in 2024 to $52.0B in 2025 and a net income margin of 19.32%. Technical indicators are bullish, with the price above key support levels and moving averages signaling upward trend. Recent news highlights strategic moves into autonomous vehicles, including robotaxi pilots in Spain and Germany, though cost management is evident through HR layoffs and AI spending caps.

The outlook for Uber is positive, driven by revenue expansion and profitability improvements, but risks include intense competition and regulatory scrutiny. Analyst consensus is strongly bullish with a $102.88 price target, suggesting significant upside potential from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About Uber Technologies Inc

Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.

Read more on UBER